T2016-001 (Ibrutinib)

Protocol Opened: 02-12-2016

Protocol Closed: 08-06-2020

Study Contacts

• Study Chair: Deepa Bhojwani, MD
• Study Vice Chair: Robin Norris, MD

Please refer to the study summary provided by TACL Ops. for your review.

Click here to be taken to the T2016-001 Ibrutinib (NCT02703272) clinicaltrials.gov web page.